TNX-103

DRUG3 trials

Sponsors

Tenax Therapeutics, Inc.

Conditions

Pulmonary HypertensionPulmonary Hypertension Associated With HFpEF

Phase 3

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Active, not recruitingNCT05983250

Tenax Therapeutics, Inc.Pulmonary Hypertension

Start: 2024-01-10End: 2028-10-30Target: 230Updated: 2026-07-24

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

RecruitingNCT07288398

Tenax Therapeutics, Inc.Pulmonary Hypertension Associated With HFpEF

Start: 2026-03-03End: 2029-06-30Target: 540Updated: 2026-08-19

Long-Term Open-Label Extension Study of Oral Levosimendan

Enrolling by invitationNCT07436689

Tenax Therapeutics, Inc.Pulmonary Hypertension Associated With HFpEF

Start: 2026-03-13End: 2029-03-01Target: 800Updated: 2026-09-09